论文部分内容阅读
化学名红霉素9-[O-(2-甲氧基乙氧基)-甲基]-肟药效分类口服大环内酯类抗生素开发单位 (法)罗塞尔·尤克拉夫公司上市厂商 (法)罗塞尔·尤克拉夫公司1988年首次上市药理与红霉素相同,本品也是通过抑制细菌细胞蛋白质合成而发挥抑菌作用。体内外研究证实,本品对A型化脓性链球菌、β-溶血性链球菌、肺炎双球菌、金黄色及表皮葡萄球菌(包括耐新青霉素菌株)、嗜肺军团菌、变异型链球菌、血液链球菌、杜克雷嗜血杆菌、Cardnerella Vaginalis、沙眼衣原体、
Chemical name Erythromycin 9- [O- (2-methoxyethoxy) -methyl] -oxime Pharmacodynamic classification Oral macrolide antibiotic development unit (law) Rossell Yoclav company listed Manufacturer (Law) Russell Yukloff company listed for the first time in 1988 and erythromycin pharmacological same, this product is through the inhibition of bacterial cell protein synthesis and play an inhibitory effect. In vivo and in vitro studies have confirmed that the product of Streptococcus pyogenes type A, β-hemolytic streptococcus, pneumococcus, Staphylococcus aureus and Staphylococcus epidermidis (including resistant strains of new penicillin), Legionella pneumophila, Streptococcus mutans, Streptococcus sobrinus, Haemophilus ducreyi, Cardnerella vaginalis, Chlamydia trachomatis,